309 related articles for article (PubMed ID: 29334883)
21. Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy.
Reid A; Stöhr W; Walker AS; Williams IG; Kityo C; Hughes P; Kambugu A; Gilks CF; Mugyenyi P; Munderi P; Hakim J; Gibb DM;
Clin Infect Dis; 2008 Apr; 46(8):1271-81. PubMed ID: 18444867
[TBL] [Abstract][Full Text] [Related]
22. Urinary β2 microglobulin can predict tenofovir disoproxil fumarate-related renal dysfunction in HIV-1-infected patients who initiate tenofovir disoproxil fumarate-containing antiretroviral therapy.
Nishijima T; Kurosawa T; Tanaka N; Kawasaki Y; Kikuchi Y; Oka S; Gatanaga H
AIDS; 2016 Jun; 30(10):1563-71. PubMed ID: 26919734
[TBL] [Abstract][Full Text] [Related]
23. The effect of Tenofovir on renal function among Ugandan adults on long-term antiretroviral therapy: a cross-sectional enrolment analysis.
Salome T; Kasamba I; Mayanja BN; Kazooba P; Were J; Kaleebu P; Munderi P;
AIDS Res Ther; 2016; 13(1):28. PubMed ID: 27582777
[TBL] [Abstract][Full Text] [Related]
24. Long Term Exposure to Tenofovir Disoproxil Fumarate-Containing Antiretroviral Therapy Is Associated with Renal Impairment in an African Cohort of HIV-Infected Adults.
Agbaji OO; Abah IO; Ebonyi AO; Gimba ZM; Abene EE; Gomerep SS; Falang KD; Anejo-Okopi J; Agaba PA; Ugoagwu PO; Agaba EI; Imade GE; Sagay AS; Okonkwo P; Idoko JA; Kanki PJ
J Int Assoc Provid AIDS Care; 2019; 18():2325958218821963. PubMed ID: 30672363
[TBL] [Abstract][Full Text] [Related]
25. Renal function and risk factors for renal disease for patients receiving HIV pre-exposure prophylaxis at an inner metropolitan health service.
Drak D; Barratt H; Templeton DJ; O'Connor CC; Gracey DM
PLoS One; 2019; 14(1):e0210106. PubMed ID: 30653509
[TBL] [Abstract][Full Text] [Related]
26. Change in Renal Function among HIV-Infected Koreans Receiving Tenofovir Disoproxil Fumarate-Backbone Antiretroviral Therapy: A 3-Year Follow-Up Study.
Lee KH; Lee JU; Ku NS; Jeong SJ; Han SH; Choi JY; Song YG; Kim JM
Yonsei Med J; 2017 Jul; 58(4):770-777. PubMed ID: 28540990
[TBL] [Abstract][Full Text] [Related]
27. Impact of tenofovir dose adjustment on both estimated glomerular filtration rate and tenofovir trough concentration.
Bregigeon S; Solas C; Faucher O; Obry-Roguet V; Tamalet C; Poizot-Martin I
Antivir Ther; 2017; 22(6):529-533. PubMed ID: 28195560
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to tenofovir-emtricitabine (TDF-FTC) co-formulation (Truvada) in virologically suppressed HIV-infected patients on HAART.
Palacios R; Hidalgo C; Ríos MJ; Rivero A; Muñoz L; Lozano F; Gutiérrez-Ravé V; Gálvez MC; del Arco A; Santos J
Eur J Clin Microbiol Infect Dis; 2009 Apr; 28(4):399-402. PubMed ID: 18841401
[TBL] [Abstract][Full Text] [Related]
29. Changes in Renal Function in Patients With Chronic HBV Infection Treated With Tenofovir Disoproxil Fumarate vs Entecavir.
Trinh S; Le AK; Chang ET; Hoang J; Jeong D; Chung M; Lee MH; Wang U; Henry L; Cheung R; Nguyen MH
Clin Gastroenterol Hepatol; 2019 Apr; 17(5):948-956.e1. PubMed ID: 30130625
[TBL] [Abstract][Full Text] [Related]
30. Risk of Nephrotoxicity in Patients With Drug-Resistant Tuberculosis Treated With Kanamycin/Capreomycin With or Without Concomitant Use of Tenofovir-Containing Antiretroviral Therapy.
Perumal R; Abdelghani N; Naidu N; Yende-Zuma N; Dawood H; Naidoo K; Singh N; Padayatchi N
J Acquir Immune Defic Syndr; 2018 Aug; 78(5):536-542. PubMed ID: 29683992
[TBL] [Abstract][Full Text] [Related]
31. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study.
Mocroft A; Lundgren JD; Ross M; Fux CA; Reiss P; Moranne O; Morlat P; Monforte Ad; Kirk O; Ryom L;
Lancet HIV; 2016 Jan; 3(1):e23-32. PubMed ID: 26762990
[TBL] [Abstract][Full Text] [Related]
32. Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure.
Jose S; Hamzah L; Campbell LJ; Hill T; Fisher M; Leen C; Gilson R; Walsh J; Nelson M; Hay P; Johnson M; Chadwick D; Nitsch D; Jones R; Sabin CA; Post FA;
J Infect Dis; 2014 Aug; 210(3):363-73. PubMed ID: 24585896
[TBL] [Abstract][Full Text] [Related]
33. Renal function of MDR-TB patients treated with kanamycin regimens or concomitantly with antiretroviral agents.
Sagwa EL; Ruswa N; Mavhunga F; Rennie T; Mengistu A; Mekonen TT; Leufkens HGM; Mantel-Teeuwisse AK
Int J Tuberc Lung Dis; 2017 Dec; 21(12):1245-1250. PubMed ID: 29297444
[TBL] [Abstract][Full Text] [Related]
34. Prognostic model for nephrotoxicity among HIV-positive Zambian adults receiving tenofovir disoproxil fumarate-based antiretroviral therapy.
Chabala FW; Siew ED; Mutale W; Mulenga L; Mweemba A; Goma F; Banda N; Kaonga P; Wester WC; Heimburger DC; Aliyu MH; Munkombwe D
PLoS One; 2021; 16(7):e0252768. PubMed ID: 34252117
[TBL] [Abstract][Full Text] [Related]
35. Prospective Study to Assess Progression of Renal Markers after Interruption of Tenofovir due to Nephrotoxicity.
Bonjoch A; Echeverría P; Perez-Alvarez N; Puig J; Estany C; Clotet B; Negredo E
Biomed Res Int; 2016; 2016():4380845. PubMed ID: 28078289
[No Abstract] [Full Text] [Related]
36. Long term renal function in Asian HIV-1 infected adults receiving tenofovir disoproxil fumarate without protease inhibitors.
Liegeon G; Harrison L; Nechba A; Halue G; Banchongkit S; Nilmanat A; Yutthakasemsunt N; Pathipvanich P; Thongpaen S; Lertkoonalak R; Althaus T; Lallemant M; Mary JY; Jourdain G
J Infect; 2019 Nov; 79(5):454-461. PubMed ID: 31401085
[TBL] [Abstract][Full Text] [Related]
37. Renal Toxicity of Concomitant Exposure to Tenofovir and Inhibitors of Tenofovir's Renal Efflux Transporters in Patients Infected With HIV Type 1.
Rokx C; Alshangi H; Verbon A; Zietse R; Hoorn EJ; Rijnders BJ
J Infect Dis; 2016 Feb; 213(4):561-8. PubMed ID: 26401025
[TBL] [Abstract][Full Text] [Related]
38. The impact of tenofovir disoproxil fumarate on kidney function: four-year data from the HIV-infected outpatient cohort.
Monteiro N; Branco M; Peres S; Borges F; Mansinho K
J Int AIDS Soc; 2014; 17(4 Suppl 3):19565. PubMed ID: 25394072
[TBL] [Abstract][Full Text] [Related]
39. Treatment-limiting renal tubulopathy in patients treated with tenofovir disoproxil fumarate.
Hamzah L; Jose S; Booth JW; Hegazi A; Rayment M; Bailey A; Williams DI; Hendry BM; Hay P; Jones R; Levy JB; Chadwick DR; Johnson M; Sabin CA; Post FA
J Infect; 2017 May; 74(5):492-500. PubMed ID: 28130143
[TBL] [Abstract][Full Text] [Related]
40. Tenofovir disoproxil fumarate-associated hypophosphatemia as determined by fractional excretion of filtered phosphate in HIV-infected patients.
Cheng CY; Chang SY; Lin MH; Ku SY; Sun NL; Cheng SH
J Infect Chemother; 2016 Nov; 22(11):744-747. PubMed ID: 27613487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
